Colorado-based miRagen Therapeutics has expanded its senior leadership team with the appointments of Adam Levy as chief business officer, succeeding Christopher Mori who now becomes chief operating officer.
Levy (pictured right) joins the clinical-stage biopharmaceutical company from Wedbush Securities, a healthcare banking group, where he served as senior vice president from 2013.
Prior to this, Levy held positions of increasing responsibility in investment banking at Merrill Lynch and Jeffries, working primarily in the life sciences sector.
Meanwhile, Mori (pictured below) brings over 25 years of strategic and operational experience to his new role at miRagen Therapeutics.
Prior to joining as chief business officer, Mori served as interim chief financial officer at Alethia Biotherapeutics, where he currently serves as an independent director.
He has held a number of executive leadership positions, including chief operating officer at Ambit Biosciences Corporation and vice president of business development at Agensys, and spent 20 years at GlaxoSmithKline in a variety of roles.
Levy said: “With two novel programmes in the clinic and a focus on diseases with high unmet medical need, I believe miRagen is poised to make a difference in the lives of patients.
“I am excited to join this talented team and contribute to the success of miRagen Therapeutics as we develop our pipeline of product candidate across multiple disease areas.”